INR Tracker was launched in April, 2012 as a solution for individuals taking blood thinners.
International Normalized Ratio (INR) is a blood test that measures the time it takes for blood to clot. This test is administered on people taking anticoagulants.
People on blood thinners such as Warfarin need to monitor their INR very carefully at all times, because if their INR is not in a therapeutic range, their Warfarin wont work properly and they will be in danger of serious bleeding, blood clots, stroke and heart attacks. The reason people on Warfarin must constantly have their INR checked is because Warfarin is dangerous and difficult to regulate. Warfarin is extremely sensitive to things like exercise, over the counter medications, and most specifically, Vitamin K.
Vitamin K is the antidote for Warfarin and is found in a myriad of commonly used foods. Unfortunately, it is not mandated by law to have Vitamin K listed on nutrition labels which makes monitoring Vitamin K intake very difficult.
INR Tracker lets people track their Vitamin K down to the microgram with our database of 7000+ foods made by the United States Department of Agriculture. With INR Tracker, people can know exactly how much Vitamin K they've had at all times. In addition, INR Tracker allows patients to track their drug dosages, missed/extra dosages, exercise, weight and other important INR factors.
With over 2 million people going on Warfarin each year, INR Tracker is a much needed solution.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2012
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was INRTracker founded?
INRTracker was founded in 2012.
What industry is INRTracker in?
INRTracker operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is INRTracker based?
INRTracker is headquartered in San Francisco, United States.
Find investors for your startup like INRTracker
Gritt sends AI-personalised outreach to each investor — from your Gmail
